DelveInsight’s “RNAi Technology Market Insights and Market Forecast – 2034” report delivers an in-depth understanding of the RNAi Technology, historical and forecasted market trends across North America, Europe, Asia-Pacific, and Rest of World.
Key Takeaways from the RNAi Technology Market Report
- In September 2025, Novartis AG announced a collaboration valued at up to USD 4.165 billion with Shanghai Argo to develop cardiovascular RNAi assets.
- The RNAi Technology market is estimated at USD 1.65 billion in 2025 and is projected to reach USD 5.55 billion by 2034, growing at a CAGR of 14.4% during the forecast period from 2026 to 2034.
- By molecule type, the siRNA segment dominated the market with a 68% share in 2025, given its role in nearly all approved RNAi therapeutics and late-stage clinical programs.
- By application, drug discovery and development led the market with a 69% share in 2025, reflecting RNAi’s essential role in target validation and therapeutic development.
- By delivery technology, GalNAc conjugates held the largest share at 46% in 2025, having transformed liver-directed delivery through infrequent, subcutaneous dosing.
- Pharmaceutical and biotechnology companies accounted for 64% of the market by end user in 2025, driving discovery, manufacturing, and commercialization of RNAi therapeutics.
- North America dominated the global market with a 45% revenue share in 2025, while Asia-Pacific is the fastest-growing region, led by China.
- In March 2025, Alnylam Pharmaceuticals, Inc. received FDA approval of AMVUTTRA (vutrisiran) for the cardiomyopathy of transthyretin-mediated amyloidosis, the first RNAi therapeutic shown to reduce cardiovascular death, hospitalizations, and urgent heart failure visits.
- The RNAi Technology Companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk A/S (Dicerna), Silence Therapeutics, Novartis AG, Ionis Pharmaceuticals, Thermo Fisher Scientific, Merck KGaA, Sirnaomics, and Sanofi S.A., among others.
RNAi Technology Epidemiology and Market Segmentation
- RNAi Technology Market by Molecule Type: siRNA, miRNA, shRNA, Others
- RNAi Technology Market by Application: Drug Discovery and Development, Therapeutics, Functional Genomics
- RNAi Technology Market by Delivery Technology: GalNAc Conjugates, Lipid Nanoparticles, Polymer and Other Carriers, Viral Vectors
- RNAi Technology Market by Therapeutic Area: Rare Genetic Disorders, Cardiometabolic Disorders, Oncology, Hepatic and Infectious Diseases, Neurological and Other Disorders
- RNAi Technology Market by End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research and Manufacturing Organizations
RNAi Technology Market Outlook
RNA interference is a naturally occurring biological process in which small RNA molecules regulate gene expression by degrading or blocking specific messenger RNA sequences, thereby silencing targeted genes and preventing the production of disease-associated proteins. The RNAi Technology Market harnesses this mechanism through siRNA, miRNA, and shRNA to silence genes previously considered undruggable by small molecules or antibodies. The market spans both therapeutic applications, treating rare genetic, cardiometabolic, and hepatic diseases, and research applications supporting drug discovery, target validation, and functional genomics. Central to the field are targeted delivery platforms, including GalNAc conjugates and lipid nanoparticles, which have overcome earlier barriers of instability, poor uptake, and off-target effects.
Growth is driven by a rapidly expanding portfolio of approved siRNA therapeutics, with over ten siRNA-based drugs now approved, alongside breakthroughs in targeted delivery and a deep clinical pipeline exceeding 150 active interventional trials. Major strategic partnerships, including a collaboration valued at up to USD 4.165 billion between Novartis and Shanghai Argo and Novo Nordisk’s acquisition of Dicerna, are accelerating development and drawing large pharmaceutical companies into the field. However, delivery beyond the liver, high development costs, and evolving regulatory frameworks continue to temper the pace of growth.
RNAi Technology Pipeline The RNAi Technology Pipeline continues to diversify across molecule types and delivery technologies, targeting rare genetic disorders, cardiometabolic conditions, oncology, and hepatic and infectious diseases. Recent developments include Arrowhead Pharmaceuticals’ phase 2 evaluation of ARO-HIF2 for renal cell carcinoma and Sirnaomics’ partnership exploring RNAi applications in aesthetic medicine, illustrating the pipeline’s reach beyond its hepatic origins into oncology and dermatology.
Scope of the RNAi Technology Market Report
- Coverage- Global
- Study Period- 2023-2034
- RNAi Technology Companies- Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk A/S (Dicerna), Silence Therapeutics, Novartis AG, Ionis Pharmaceuticals, Thermo Fisher Scientific, Merck KGaA, Sirnaomics, and Sanofi S.A., and others.
- RNAi Technology Market Segments- Molecule Type, Application, Delivery Technology, Therapeutic Area, End User
- RNAi Technology Market Dynamics- Market Drivers and Market Restraints
Latest Reports offered by Delveinsight
ly3454738 drug insight | maple syrup urine disease market | mismatch repair deficiency market | moderate psoriasis market | myopic macular degeneration market | nasopharyngeal cancer market | ncfb market | nephrotic syndrome market | neuromodulation devices market | non-st segment elevation acute coronary | nonmelanoma skin cancer market | nonmuscle invasive bladder cancer market | nosocomial pneumonia market | ocular inflammation and pain market | ocular melanoma market | oncolytic virus cancer therapy pipeline | orthopedic trauma devices market | pacemakers market | pancreatic adenocarcinoma market | parp inhibitor market | partial seizure market | pediatric central nervous system tumors | peripheral neuropathic pain market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk